Rachel E. Gicquelais

Rachel E. Gicquelais

Auto-generated profile, based on publicly available information

Rachel E. Gicquelais

Department of Population Health Sciences, University of Wisconsin-Madison School of Medicine and Public Health, Madison, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMaria Sellitto
Maria Sellitto
GBGuoyun Bai
Guoyun Bai
GSGloria Serena
Gloria Serena
WFW. Florian Fricke
W. Florian Fricke
CSCraig Sturgeon
Craig Sturgeon
AFAlessio Fasano
Alessio Fasano
Celiac disease (CD) is a unique autoimmune disorder in which the genetic factors (DQ2/DQ8) and the environmental trigger (gluten) are known and necessary but not sufficient for its development. Other environmental components contributing to CD are poorly understood. Studies suggest that aspects of gluten intake might influence the risk of CD occurrence and timing of its onset, i.e., the amount and quality of ingested gluten, together with the pattern of infant feeding and the age at which gluten is introduced in the diet. In this study, we hypothesize that the intestinal microbiota as a whole rather than specific infections dictates the switch from tolerance to immune response in genetically susceptible individuals. Using a sample of infants genetically at risk of CD, we characterized the longitudinal changes in the microbial communities that colonize infants from birth to 24 months and the impact of two patterns of gluten introduction (early vs. late) on the gut microbiota and metabolome, and the switch from gluten tolerance to immune response, including onset of CD autoimmunity. We show that infants genetically susceptible to CD who are exposed to gluten early mount an immune response against gluten and develop CD autoimmunity more frequently than at-risk infants in which gluten exposure is delayed until 12 months of age. The data, while derived from a relatively small number of subjects, suggest differences between the developing microbiota of infants with genetic predisposition for CD and the microbiota from infants with a non-selected genetic background, with an overall lack of bacteria of the phylum Bacteriodetes along with a high abundance of Firmicutes and microbiota that do not resemble that of adults even at 2 years of age. Furthermore, metabolomics analysis reveals potential biomarkers for the prediction of CD. This study constitutes a definite proof-of-principle that these combined genomic and metabolomic approaches will be key to deciphering the role of the gut microbiota on CD onset.

1 June 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
Carl LatkinCarl Latkin
Carl Latkin
RGRachel E. Gicquelais
Rachel E. Gicquelais
CCCatie Clyde
Catie Clyde
LDLauren Dayton
Lauren Dayton
MDMelissa Davey-Rothwell
Melissa Davey-Rothwell
KTKarin Tobin
Karin Tobin

10 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RGRachel E. Gicquelais
Rachel E. Gicquelais
ABAmy S. B. Bohnert
Amy S. B. Bohnert
LTLaura Thomas
Laura Thomas
BFBetsy Foxman
Betsy Foxman
Murine models suggest that opioids alter the gut microbiota, which may impact opioid tolerance and psychopathology. We examined how gut microbiota characteristics related to use of opioid agonists and antagonists among people receiving outpatient addiction treatment. Patients (n = 46) collected stool samples and were grouped by use of opioid agonists (heroin, prescription opioids), antagonists (naltrexone), agonist–antagonist combinations (buprenorphine–naloxone), or neither agonists nor antagonists within the month before enrollment. We sequenced the V4 region of the 16S rRNA gene using Illumina MiSeq to examine how alpha diversity, enterotypes, and relative abundance of bacterial genera varied by opioid agonist and antagonist exposures. Compared to 31 participants who used neither agonists nor antagonists, 5 participants who used opioid agonists (without antagonists) had lower microbiota diversity, Bacteroides enterotypes, and lower relative abundance of Roseburia, a butyrate producing genus, and Bilophila, a bile acid metabolizing genus. There were no differences in gut microbiota features between those using agonist + antagonists (n = 4), antagonists only (n = 6), and neither agonists nor antagonists. Similar to murine morphine exposure models, opioid agonist use was associated with lower microbiota diversity. Lower abundance of Roseburia and Bilophila may relate to the gut inflammation/permeability and dysregulated bile acid metabolism observed in opioid-exposed mice.

7 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LDLauren Dayton
Lauren Dayton
RGRachel E Gicquelais
Rachel E Gicquelais
KTKarin Tobin
Karin Tobin
MDMelissa Davey-Rothwell
Melissa Davey-Rothwell
OFOluwaseun Falade-Nwulia
Oluwaseun Falade-Nwulia
CLCarl Latkin
Carl Latkin
Fatal opioid overdose is a pressing public health concern in the United States. Addressing barriers and augmenting facilitators to take-home naloxone (THN) access and administration could expand program reach in preventing fatal overdoses. THN access (i.e., being prescribed or receiving THN) was assessed in a Baltimore, Maryland-based sample of 577 people who use opioids (PWUO) and had a history of injecting drugs. A sub-analysis examined correlates of THN administration among those with THN access and who witnessed an overdose (N = 345). Logistic generalized estimating equations with robust standard errors were used to identify facilitators and barriers to accessing and using THN. The majority of PWUO (66%) reported THN access. In the multivariable model, decreased THN access was associated with the fear that a person may become aggressive after being revived with THN (aOR: 0.55, 95% CI: 0.35–0.85), police threaten people at an overdose event (aOR: 0.68, 95% CI: 0.36–1.00), and insufficient overdose training (aOR: 0.43, 95% CI: 0.28–0.68). Enrollment in medication-assisted treatment, personally experiencing an overdose, and graduating from high school were associated with higher access. About half (49%) of PWUO with THN access and who had witnessed an overdose reported having administered THN. THN use was positively associated with “often” or “always” carrying THN (aOR: 3.47, 95% CI: 1.99–6.06), witnessing more overdoses (aOR:5.18, 95% CI: 2.22–12.07), experiencing recent homelessness, and injecting in the past year. THN use was reduced among participants who did not feel that they had sufficient overdose training (aOR: 0.56, 95% CI: 0.32–0.96). THN programs must bolster confidence in administering THN and address barriers to use, such as fear of a THN recipient becoming aggressive. Normative change around carrying THN is an important component in an overdose prevention strategy.

9 July 2020 in Substance Use & Misuse
Verified
Journal Article
Closed access
AWAbigail K. Winiker
Abigail K. Winiker
KTKarin E. Tobin
Karin E. Tobin
RGRachel E. Gicquelais
Rachel E. Gicquelais
JOJill Owczarzak
Jill Owczarzak
Carl LatkinCarl Latkin
Carl Latkin
Rates of death from opioid overdose continue to rise in the United States. One harm reduction strategy designed to reduce fatal overdose risk among people who inject drugs (PWID) is an advisory to ...

16 May 2020 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
RGRachel E. Gicquelais
Rachel E. Gicquelais
MJMary Jannausch
Mary Jannausch
ABAmy S.B. Bohnert
Amy S.B. Bohnert
LTLaura Thomas
Laura Thomas
SSSrijan Sen
Srijan Sen
AFAnne C. Fernandez
Anne C. Fernandez